Assessment of the effects of sugammadex on coagulation profiles using thromboelastographic parameters

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002133

Enrollment

100

Registered

2016-11-04

Start date

2015-11-30

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The coagulation profiles will be evaluated by thromboelastographic parameters. Patients will be divided into two groups (2mg/kg group and 4mg/kg group).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing orthopedic surgery and American Society of Anesthesiology Classification 1 or 2

Exclusion criteria

Exclusion criteria: 1. American Society of Anesthesiology Classification >2 2. Age 79 yr 3. Neuromuscular disease patients 4. Allergic history for neuromuscular blocking agents or anesthetic agents 5. Family history of malignant hyperthermia 6. Serum Cr. >= 2 times of normal value or urine output < 0.5ml/kg/hr or Glomerular filtration rate < 60 ml/hr

Design outcomes

Primary

Measure	Time frame
R value of thromboelastographic parameters;K value of thromboelastographic parameters;alpha value of thromboelastographic parameters;MA (maximum amplitude) value of thromboelastographic parameters;LY30 value of thromboelastographic parameters;CI value of thromboelastographic parameters	—

Secondary

Measure	Time frame
Prothombin time;Activated partial thromboplastin time	—

Countries

Korea, Republic of

Contacts

Public ContactWoon-Seok Kang

Konkuk University Medical Center

anesth77@gmail.com+82-2-2030-5747

Outcome results